Диссертация (1097599), страница 27
Текст из файла (страница 27)
Rheb GTPase is a direct target of TSC2GAP activity and regulates mTOR signaling. Genes & Development, 17(15),1829–34. http://doi.org/10.1101/gad.1110003Joslin, E. J., Shankaran, H., Opresko, L. K., Bollinger, N., Lauffenburger, D. A., &Wiley, H. S. (2010). Structure of the EGF receptor transactivation circuit integratesmultiple signals with cell context. Molecular bioSystems, 6(7), 1293–306.http://doi.org/10.1039/c003921g181Junttila, T. T., Akita, R.
W., Parsons, K., Fields, C., Lewis Phillips, G. D., Friedman,L. S., … Sliwkowski, M. X. (2009). Ligand-independent HER2/HER3/PI3Kcomplex is disrupted by trastuzumab and is effectively inhibited by the PI3KinhibitorGDC-0941.CancerCell,15(5),429–40.http://doi.org/10.1016/j.ccr.2009.03.020Kholodenko, B. N. (2000). Negative feedback and ultrasensitivity can bring aboutoscillations in the mitogen-activated protein kinase cascades. European Journal ofBiochemistry,267(6),1583–8.Retrievedfromhttp://www.ncbi.nlm.nih.gov/pubmed/10712587Kholodenko, B.
N., & Birtwistle, M. R. (2009). Four-dimensional dynamics of MAPKinformation-processing systems. Wiley Interdisciplinary Reviews: SystemsBiology and Medicine, 1(1), 28–44. http://doi.org/10.1002/wsbm.16Kitano, H. (2004). Cancer as a robust system: implications for anticancer therapy.Nature Reviews. Cancer, 4(3), 227–35. http://doi.org/10.1038/nrc1300Landgraf, R. (2007). HER2 therapy. HER2 (ERBB2): functional diversity fromstructurally conserved building blocks. Breast Cancer Research : BCR, 9(1), 202.http://doi.org/10.1186/bcr1633Lebedeva, G., Sorokin, A., Faratian, D., Mullen, P., Goltsov, A., Langdon, S. P., …Goryanin, I. (2012). Model-based global sensitivity analysis as applied toidentification of anti-cancer drug targets and biomarkers of drug resistance in theErbB2/3 network.
European Journal of Pharmaceutical Sciences : OfficialJournal of the European Federation for Pharmaceutical Sciences, 46(4), 244–58.http://doi.org/10.1016/j.ejps.2011.10.026Lee-Hoeflich, S. T., Crocker, L., Yao, E., Pham, T., Munroe, X., Hoeflich, K. P., …Stern, H. M. (2008). A central role for HER3 in HER2-amplified breast cancer:implications for targeted therapy.
Cancer Research, 68(14), 5878–87.http://doi.org/10.1158/0008-5472.CAN-08-0380Lemmon, M. A., & Schlessinger, J. (2010). Cell Signaling by Receptor Tyrosine182Kinases. Cell, 141(7), 1117–1134. http://doi.org/10.1016/j.cell.2010.06.011Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., … GarcíaEcheverría, C. (2008). Identification and characterization of NVP-BEZ235, a neworally available dual phosphatidylinositol 3-kinase/mammalian target ofrapamycin inhibitor with potent in vivo antitumor activity.
Molecular CancerTherapeutics, 7(7), 1851–63. http://doi.org/10.1158/1535-7163.MCT-08-0017McConnachie, G., Pass, I., Walker, S. M., & Downes, C. P. (2003). Interfacial kineticanalysis of the tumour suppressor phosphatase, PTEN: evidence for activation byanionic phospholipids.The BiochemicalJournal, 371(Pt3), 947–55.http://doi.org/10.1042/BJ20021848McLaughlin, S., Wang, J., Gambhir, A., & Murray, D.
(2002). PIP(2) and proteins:interactions, organization, and information flow. Annual Review of Biophysics andBiomolecularStructure,31,151–75.http://doi.org/10.1146/annurev.biophys.31.082901.134259Memmott, R. M., & Dennis, P. A. (2009). Akt-dependent and -independentmechanisms of mTOR regulation in cancer. Cellular Signalling, 21(5), 656–64.http://doi.org/10.1016/j.cellsig.2009.01.004Mendoza, M. C., Er, E. E., & Blenis, J. (2011). The Ras-ERK and PI3K-mTORpathways: cross-talk and compensation. Trends in Biochemical Sciences, 36(6),320–328.
http://doi.org/10.1016/j.tibs.2011.03.006Molina, M. A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J.(2001). Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonalantibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancercells.CancerResearch,61(12),4744–9.Retrievedfromhttp://www.ncbi.nlm.nih.gov/pubmed/11406546Nagashima, T., Shimodaira, H., Ide, K., Nakakuki, T., Tani, Y., Takahashi, K., …Hatakeyama, M. (2007).
Quantitative Transcriptional Control of ErbB ReceptorSignaling Undergoes Graded to Biphasic Response for Cell Differentiation.183JournalofBiologicalChemistry,282(6),4045–4056.http://doi.org/10.1074/jbc.M608653200Nagumo, Y., Faratian, D., Mullen, P., Harrison, D. J., Hasmann, M., & Langdon, S. P.(2009). Modulation of HER3 is a marker of dynamic cell signaling in ovariancancer: implications for pertuzumab sensitivity. Molecular Cancer Research :MCR, 7(9), 1563–71. http://doi.org/10.1158/1541-7786.MCR-09-0101Nakakuki, T., Birtwistle, M. R., Saeki, Y., Yumoto, N., Ide, K., Nagashima, T., …Kholodenko, B. N.
(2010). Ligand-specific c-Fos expression emerges from thespatiotemporal control of ErbB network dynamics. Cell, 141(5), 884–96.http://doi.org/10.1016/j.cell.2010.03.054Nakayama, K., Satoh, T., Igari, A., Kageyama, R., & Nishida, E. (2008). FGF inducesoscillations of Hes1 expression and Ras/ERK activation. Current Biology, 18(8),R332–R334. http://doi.org/10.1016/j.cub.2008.03.013Nguyen, L. K., Matallanas, D., Croucher, D. R., von Kriegsheim, A., & Kholodenko,B. N.
(2013). Signalling by protein phosphatases and drug development: asystems-centredview.TheFEBSJournal,280(2),751–65.http://doi.org/10.1111/j.1742-4658.2012.08522.xNik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., …Stratton, M. R. (2016).
Landscape of somatic mutations in 560 breast cancerwhole-genomesequences.Nature,534(7605),47–54.http://doi.org/10.1038/nature17676Normanno, N., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., De Luca, A., …Salomon, D. S. (2005). The ErbB receptors and their ligands in cancer: anoverview.CurrentDrugTargets,6(3),243–57.Retrievedfromhttp://www.ncbi.nlm.nih.gov/pubmed/15857286Noske, A., Kaszubiak, A., Weichert, W., Sers, C., Niesporek, S., Koch, I., … Denkert,C.
(2007). Specific inhibition of AKT2 by RNA interference results in reductionof ovarian cancer cell proliferation: Increased expression of AKT in advanced184ovariancancer.CancerLetters,246(1–2),190–200.http://doi.org/10.1016/j.canlet.2006.02.018Park, J. W., Neve, R.
M., Szollosi, J., & Benz, C. C. (2008). Unraveling the Biologicand Clinical Complexities of HER2. Clinical Breast Cancer, 8(5), 392–401.http://doi.org/10.3816/CBC.2008.n.047Pillay, C. S., Hofmeyr, J.-H. S., & Rohwer, J. M. (2011). The logic of kinetic regulationinthethioredoxinsystem.BMCSystemsBiology,5,15.http://doi.org/10.1186/1752-0509-5-15Qutub, A. A., & Popel, A. S. (2008). Reactive oxygen species regulate hypoxiainducible factor 1alpha differentially in cancer and ischemia. Molecular andCellular Biology, 28(16), 5106–19.
http://doi.org/10.1128/MCB.00060-08Rodrigues, G. A., Falasca, M., Zhang, Z., Ong, S. H., & Schlessinger, J. (2000). ANovel Positive Feedback Loop Mediated by the Docking Protein Gab1 andPhosphatidylinositol 3-Kinase in Epidermal Growth Factor Receptor Signaling.MolecularandCellularBiology,20(4),1448–1459.http://doi.org/10.1128/MCB.20.4.1448-1459.2000Roy, S. K., Srivastava, R. K., & Shankar, S.
(2010). Inhibition of PI3K/AKT andMAPK/ERK pathways causes activation of FOXO transcription factor, leading tocell cycle arrest and apoptosis in pancreatic cancer. Journal of Molecular Signaling,5, 10. http://doi.org/10.1186/1750-2187-5-10Samaga, R., Saez-Rodriguez, J., Alexopoulos, L. G., Sorger, P. K., Klamt, S., Olayioye,M., … Gilles, E. (2009).
The Logic of EGFR/ErbB Signaling: TheoreticalProperties and Analysis of High-Throughput Data. PLoS Computational Biology,5(8), e1000438. http://doi.org/10.1371/journal.pcbi.1000438Schoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., … Nielsen,U. B. (2009).
Therapeutically targeting ErbB3: a key node in ligand-inducedactivation of the ErbB receptor-PI3K axis. Science Signaling, 2(77), ra31.http://doi.org/10.1126/scisignal.2000352185Schulze, W. X., Deng, L., & Mann, M. (2005). Phosphotyrosine interactome of theErbB-receptor kinase family. Molecular Systems Biology, 1, 2005.0008.http://doi.org/10.1038/msb4100012Shankaran, H., Ippolito, D. L., Chrisler, W. B., Resat, H., Bollinger, N., Opresko, L.K., & Wiley, H. S. (2009).
Rapid and sustained nuclear–cytoplasmic ERKoscillations induced by epidermal growth factor. Molecular Systems Biology, 5,332. http://doi.org/10.1038/msb.2009.90Shor, B., Zhang, W.-G., Toral-Barza, L., Lucas, J., Abraham, R. T., Gibbons, J. J., &Yu, K. (2008). A new pharmacologic action of CCI-779 involves FKBP12independent inhibition of mTOR kinase activity and profound repression of globalprotein synthesis.
Cancer Research, 68(8), 2934–43. http://doi.org/10.1158/00085472.CAN-07-6487Sims, A. H., Zweemer, A. J. M., Nagumo, Y., Faratian, D., Muir, M., Dodds, M., …Langdon, S. P. (2012). Defining the molecular response to trastuzumab,pertuzumab and combination therapy in ovarian cancer. British Journal of Cancer,106(11), 1779–89. http://doi.org/10.1038/bjc.2012.176Sokolovski, S. G., Zolotovskaya, S. A., Goltsov, A., Pourreyron, C., South, A. P., &Rafailov, E.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
